Clinical trial
The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing…
NCT00133731 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00133731 |
|---|---|
| Title | The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention |
| Official title | A Multinational, Randomized, Double-Blind, Double-Dummy, Exploratory, Parallel Group, Dose-Ranging Phase II Study to Evaluate Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Several Intravenous Regimens of Factor Xa Inhibitor Otamixaban (XRP0673), in Comparison to Intravenous… |
| Acronym | SEPIA-PCI |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Angioplasty, Transluminal, Percutaneous Coronary |
| Intervention type | Drug, Procedure |
| Interventions | Otamixaban (XRP0673), Unfractionated Heparin, Percutaneous Coronary Intervention |
| Enrollment | 947 |
| Start date | Sep 1, 2004 |
| Completion | Oct 1, 2005 |
| First posted | Aug 24, 2005 |
| Last update posted | Jul 2, 2008 |
| Countries | Belgium, Canada, Czechia, France, Germany, Netherlands, Slovakia, South Africa, Spain, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: